Common Heartburn Drug Linked to Significantly Increased Stomach Cancer Risk, Study finds
PARIS – A major 24-year study, dubbed “NordGETS,” has revealed a striking correlation between long-term use of proton pump inhibitors (PPIs) and an 83% increased risk of stomach cancer, particularly in individuals under 65. The research, analyzing the health records of nearly 18,800 people across Finland, Denmark, Iceland, Sweden, and Norway – including 1,790 with gastric neuroendocrine neoplasms (tumors in the stomach wall) and 17,000 healthy controls – points to a potential danger for the millions who rely on these medications for heartburn and gastroesophageal reflux.
PPIs work by reducing stomach acid production. Commonly prescribed medications in this class include lansoprazole (Lanzor®, Ogast®), pantoprazole (Eupantol®, Inipom®), esomeprazole (Inexium®), rabeprazole (Pariet®), omeprazole (Mopral®, Zoltum®), and their generic equivalents. The study accounted for confounding factors like Helicobacter pylori infection, a known contributor to stomach inflammation and gastritis.
Researchers found that prolonged PPI use can lead to an overproduction of gastrin, a hormone that stimulates stomach cells. this overstimulation may contribute to the growth of tumors.
Despite the alarming findings,experts caution against abruptly stopping PPI treatment. Dr. Eivind Ness-Jensen emphasized, “The incidence of gastric NEN is very low and the absolute risk of developing such tumors remains low, even in PPI consumers. These results should therefore not call into question the use of PPIs in patients with an appropriate indication.” He advises individuals currently on PPIs to consult with their doctor for personalized medical advice.
